Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06524973

Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers

This clinical trial evaluates the impact of telehealth self-management coaching sessions on quality of life in pancreatic cancer survivors and their family care givers (FCGs). Patients with pancreatic cancer experience many symptoms because of the disease and treatment, which can have a negative impact on quality of life. Patients and their families have unmet needs during treatment, including a lack of quality of life programs that offer support to patients. Supporting patients and families on managing the physical symptoms, emotional well-being, social well-being and spiritual well-being with telehealth self-management coaching sessions may help improve quality of life, manage symptoms from treatment, and support families in their role as caregivers during treatment.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

City of Hope at Arcadia, Arcadia, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • • PATIENT: Documented informed consent of the participant and/or legally authorized representative
  • Assent, when appropriate, will be obtained per institutional guidelines
  • PATIENT: Age: ≥ 18 years
  • PATIENT: Eastern Cooperative Oncology Group (ECOG) ≤ 2
  • PATIENT: Ability to read and understand English or Spanish for questionnaires
  • PATIENT: Subjects must have histologically or cytologically confirmed diagnosis of metastatic pancreatic adenocarcinoma who are within 8 weeks of initial diagnosis
  • FAMILY CARE GIVER: Documented informed consent of the participant and/or legally authorized representative
  • Assent, when appropriate, will be obtained per institutional guidelines
  • FAMILY CARE GIVER: Age: ≥ 18 years
  • FAMILY CARE GIVER: Ability to read and understand English or Spanish for questionnaires
  • FAMILY CARE GIVER: A family member or friend identified by the patient and defined as a person who knows the patient well and is involved in the patient's medical care

Exclusion criteria

  • • An employee who is under the direct/ indirect supervision of the principal investigator (PI)/ a co-investigator/ the study manager
  • A direct study team member

Treatment and study plan

Telemedicine

Other

Attend telehealth self-management coaching sessions

Counseling

Other

Attend telehealth self-management coaching sessions

Best Practice

Other

Receive standard of care

Questionnaire Administration

Other

Ancillary studies

Inrweview

Other

Ancillary studies

Primary outcomes

  1. Patient reported quality of life (QOL)

    Time frame: At baseline and at 3 months post randomization

    Patient reported quality of life will be assessed by the Functional Assessment of Cancer Therapy- Hepatobiliary (FACT-Hep) quality of life score. The primary analysis will be a treatment group comparison of the QOL at 3 months via linear regression model, with adjustment for baseline FACT-Hep score and stratification factors. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. The dependent variables will be transformed to approximate normality as appropriate.

Secondary outcomes

  1. Enrollment rate

    Time frame: Up to 25 months

    Feasibility of the intervention will be defined as at least 60% of eligible participants enrolling. Descriptive statistics will be used to summarize the feasibility of the intervention. Reasons for non-participation will be recorded and used to make needed modifications for improvement in future studies.

  2. Intervention completion rate

    Time frame: Up to 6 months

    Feasibility of the intervention will be defined as at least 60% of participants completing ≥ 80% of the intervention (4 of 6 sessions). Descriptive statistics will be used to summarize the feasibility of the intervention. Reasons for attrition will be recorded and used to make needed modifications for improvement in future studies.

  3. Rate of participants completing any follow-up assessments

    Time frame: Up to 6 months

    Feasibility of the intervention will be defined as at least 60% of participants completing any follow-up assessments after randomization. Descriptive statistics will be used to summarize the feasibility of the intervention. Reasons for attrition will be recorded and used to make needed modifications for improvement in future studies.

  4. Participant experience

    Time frame: Up to 6 months

    Participant experiences with the intervention will be explored through qualitative data (structured exit interviews) from participants randomized to the intervention group and analyzed using content analysis approach. Interviews will be transcribed and data analyzed. Transcripts will be imported for the development of analytic categories, data coding, and review of coded data. Codes will be sorted into themes based on links and relationship.

  5. Patient reported symptom severity

    Time frame: At baseline and at 3 and 6 months post randomization

    Treatment group comparisons will be assessed via repeated measures linear regression models with adjustment for baseline value of the outcome including sex and age and stratification factors. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. The dependent variables will be transformed to approximate normality as appropriate.

  6. Patient reported psychological distress

    Time frame: At baseline and at 3 and 6 months post randomization

    Patient reported psychological distress will be measured using the National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT). Treatment group comparisons will be assessed via repeated measures linear regression models with adjustment for baseline value of the outcome including sex and age and stratification factors. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. The dependent variables will be transformed to approximate normality as appropriate.

  7. Family care giver (FCG) psychological distress

    Time frame: At baseline and at 3 and 6 months post randomization

    FCG reported psychological distress will be measured using the NCCN DT. Treatment group comparisons will be assessed via repeated measures linear regression models with adjustment for baseline value of the outcome including sex and age and stratification factors. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. The dependent variables will be transformed to approximate normality as appropriate.

  8. FCG caregiving burden

    Time frame: At baseline and at 3 and 6 months post randomization

    FCG caregiving burden will be measured using the Montgomery Borgatta Caregiver Burden Scale. Treatment group comparisons will be assessed via repeated measures linear regression models with adjustment for baseline value of the outcome including sex and age and stratification factors. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. The dependent variables will be transformed to approximate normality as appropriate.

  9. FCG QOL

    Time frame: At baseline and at 3 and 6 months post randomization

    FCG QOL will be measured using City of Hope Quality of Life-Family questionnaire. Treatment group comparisons will be assessed via repeated measures linear regression models with adjustment for baseline value of the outcome including sex and age and stratification factors. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. The dependent variables will be transformed to approximate normality as appropriate.

  10. Overall survival

    Time frame: From initiation of intervention to death from any cause, up to 6 months

Other outcomes

  1. Chemotherapy in last 14 days of life

    Time frame: At 3 and 6 months post randomization

  2. Emergency room visits in the last days of life

    Time frame: At 3 and 6 months post randomization

  3. Intensive care unit admissions in the last 30 days of life

    Time frame: At 3 and 6 months post randomization

  4. Hospice care for less than 3 days before death

    Time frame: At 3 and 6 months post randomization

Study contacts

Contact information is provided by the study sponsor or research team.

Vincent Chung, MD

CONTACT

[email protected]

626-359-8111

Sponsors and collaborators

Lead sponsor

City of Hope Medical Center

Other

Registry information

Official study title

Impacting Quality of Life and Pancreatic Cancer Survivorship Through a Telehealth Intervention

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Jul 29, 2024
Registry last updated
Nov 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.